Evolution of Biocatalysis at Novartis over the last 40 Years

Authors

  • Elina Siirola Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Fabian Eggimann Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Charles Moore Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Kirsten Schroer Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Alexandra Vargas Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Theo Peschke Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Thierry Schlama Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108
  • Radka Snajdrova Global Discovery Chemistry, Novartis Institute for Biomedical Research, Basel, CH-4108

DOI:

https://doi.org/10.2533/chimia.2023.376

PMID:

38047776

Keywords:

Biocatalysis, Bioinformatics, Enzyme evolution, Late-stage functionalization, Metabolite synthesis

Abstract

The fortieth anniversary of biocatalysis started at Ciba-Geigy and later at Novartis is a great time to pause and reflect on development of science and technology in this field. Enzyme-based synthesis became a highly valued enabling tool for pharmaceutical research and development over the last decades. In this perspective we aim to discuss how the scientific approaches and trends evolved over the time and present future challenges and opportunities.

Downloads

Published

2023-06-28

Issue

Section

Scientific Articles

How to Cite

[1]
E. Siirola, F. Eggimann, C. Moore, K. Schroer, A. Vargas, T. Peschke, T. Schlama, R. Snajdrova, Chimia 2023, 77, 376, DOI: 10.2533/chimia.2023.376.